Mimedx Group (MDXG) risk factors, FY2024 10-K

Risks Related to Our Business and Industry

1. 01If we do not successfully execute our priorities, our business, operating results and financial condition could be adversely affected
2. 02We are in a highly competitive and evolving field and face competition from well-established tissue processors and medical device manufacturers, as well as new market entrants
3. 03Rapid technological change could cause our products to become obsolete and, if we do not enhance our product offerings through our research and development efforts or business development and inorganic activities, we may be unable to compete effectively
4. 04Many of our products depend on the availability of tissue from human donors, and any disruption in supply could adversely affect our business
5. 05Our business and success are materially dependent on attracting and retaining members of our senior leadership team to formulate and execute the Company’s business plans and our sales team to market our products
6. 06Our revenues depend on adequate reimbursement from public and private insurers and health systems and changes to the ways in which our products are reimbursed in various sites of service could adversely impact our financial results
7. 07uncertainty may exist as to the reimbursement status of new healthcare products by third-party payers. Although EPIFIX and EPICORD have coverage with the majority of large payers, a significant number of public and private insurers currently do not cover or reimburse our other products
8. 08Our revenue, results of operations and cash flows may suffer upon the loss of a Group Purchasing Organization or Integrated Delivery Network
9. 09We contract with and are dependent upon independent sales agents and distributors
10. 10Disruption of our processing facilities could adversely affect our business, financial condition and results of operations
11. 11To be commercially successful, we must educate physicians, where appropriate, how and when our products are proper alternatives to existing treatments and that our products should be used in their procedures
12. 12If we cannot successfully address quality issues that may arise with our products, our brand reputation could suffer, and our business, financial condition, and results of operations could be adversely impacted
13. 13The formation of physician-owned distributorships (“PODs”) could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships
14. 14We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance
15. 15The products we offer are derived from human and animal tissue and therefore have the potential for disease transmission
16. 16We may implement a product recall or voluntary market withdrawal, which could significantly increase our costs, damage our reputation, disrupt our business and adversely affect our business, results of operations and financial condition
17. 17A cyberattack or significant disruptions of our information technology systems could adversely affect our business, results of operation and financial condition
18. 18We may expand or contract our business through acquisitions, divestitures, licenses, investments, and other commercial arrangements with other companies or technologies, which may adversely affect our business, results of operations and financial condition
19. 19A portion of our revenues and accounts receivable come from government accounts
20. 20New lines of business or new products and services may subject us to additional risks
21. 21Our international expansion and operations outside the U.S. expose us to risks associated with international sales and operations

Risks Related to Regulatory Approval of Our Products and Other Government Regulations

1. 22HELIOGEN, our first xenograft product offering, falls into an FDA classification that requires the submission of a Premarket Notification (510(k)) to the FDA. The 510(k) was obtained and is owned by our contracted manufacturing partner, Regenity Biosciences
2. 23Obtaining and maintaining the necessary regulatory approvals, including conducting clinical trials, for certain of our products or potential products could be expensive and time consuming
3. 24Our business is subject to extensive regulation by the FDA and other authorities, which is costly, and our failure to comply could result in negative effects on our business, results of operations and financial condition
4. 25The FDA’s regulation of HCT/Ps may continue to evolve. Complying with any such new regulatory requirements may entail significant time delays and expense, which could have an adverse effect on our business, results of operations and financial condition
5. 26We may be subject to fines, penalties, injunctions and other sanctions if we are deemed to be promoting the use of our products for unapproved, or off-label, uses
6. 27We and our sales representatives, whether employees or independent contractors, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause an adverse effect on our business, results of operations and financial condition
7. 28of these laws, or even a government investigation or inquiry into the same, would likely result in a material adverse effect on the market price of our Common Stock, as well as on our business, results of operations, and financial condition
8. 29Our results of operations may be adversely affected by current and potential future healthcare reforms
9. 30We may fail to obtain or maintain foreign regulatory approvals to market our products in other countries
10. 31Federal and state laws that protect the privacy and security of personal information may increase our costs and limit our ability to collect and use that information and subject us to liability if we are unable to fully comply with such laws

Risks Related to Our Intellectual Property

1. 32Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which could have an adverse effect on our business, results of operations and financial condition
2. 33We may become subject to claims of infringement of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages
3. 34We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets, proprietary or confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors

Risks Related to Our Consolidated Financial Statements, Internal Controls and Related Matters

1. 35If we fail to maintain adequate internal control over financial reporting in the future, this could adversely affect our business, financial condition and operating results

Risks Related to the Securities Markets and Ownership of Our Common Stock

1. 36Our indebtedness may adversely affect our financial health
2. 37The restrictive covenants in the Citizens Credit Agreement, and the Company’s obligation to make payments under the Citizens Credit Agreement, limit our operating and financial flexibility and may adversely affect our business, results of operations and financial condition
3. 38EW Healthcare Partners and its interests may conflict with those of our other shareholders
4. 39The price of our Common Stock has been, and will likely continue to be, volatile
5. 40Securities analysts may elect not to report on our common stock or may issue negative reports that adversely affect the stock price
6. 41Fluctuations in revenue or results of operations could cause additional volatility in our stock price
7. 42We do not intend to pay cash dividends on our Common Stock
8. 43Certain provisions of Florida law and anti-takeover provisions in our organizational documents may discourage or prevent a change of control, even if an acquisition would be beneficial to shareholders, which could affect our share price adversely and prevent attempts by shareholders to remove current management